<DOC>
	<DOCNO>NCT01638533</DOCNO>
	<brief_summary>This phase I trial study side effect best dose romidepsin treat patient lymphoma , chronic lymphocytic leukemia , solid tumor liver dysfunction . Romidepsin may stop growth cancer cell enter cancer cell block activity protein important cancer 's growth survival .</brief_summary>
	<brief_title>Romidepsin Treating Patients With Lymphoma , Chronic Lymphocytic Leukemia , Solid Tumors With Liver Dysfunction</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish safety tolerability romidepsin give day 1 , 8 , 15 28 day cycle patient vary degree liver dysfunction ( mild , moderate severe ) . II . To establish maximum tolerate dose ( MTD ) appropriate dose recommendation romidepsin patient . III . To characterize pharmacokinetics ( PK ) romidepsin patient vary degree liver dysfunction . SECONDARY OBJECTIVES : I . To explore correlation Child-Pugh classification liver dysfunction observe toxicity plasma PK romidepsin administration . II . To document preliminary evidence antitumor activity tolerable dos romidepsin patient vary degree liver dysfunction . OUTLINE : This dose-escalation study . Patients receive romidepsin intravenously ( IV ) 4 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Patients must histologically cytologically confirm ( original diagnosis subsequent recurrence progression ) lymphoma , chronic lymphocytic lymphoma ( CLL ) solid tumor ; patient lymphoma CLL must radiologically clinically evaluable disease , refractory standard therapy define relapse within 6 month last treatment ( see note ) ; patient solid tumor must radiologically clinically evaluable disease metastatic , unresectable , progressive , recurrent , standard curative measure exist longer effective Patients liver mass , raise alphafetoprotein level ( &gt; = 500 ng/mL ) positive serology hepatitis , consistent diagnosis hepatocellular carcinoma eligible without need pathologic confirmation diagnosis Patients prostate cancer , renal cell cancer , neuroendocrine tumor , lung cancer , colorectal cancer , soft tissue sarcoma , glioma thyroid cancer exclude normal mild cohort due lack efficacy tumor type phase 2 study ; patient breast , pancreatic , bladder , head neck cancer , well melanoma malignancy eligible Note : patient prostate cancer , renal cell cancer , lung cancer , colorectal cancer , soft tissue sarcoma , glioma thyroid cancer allow enroll moderate severe cohort provide patient : Sign separate consent form outline lack efficacy observe prior study Are consent study protocolspecified designee longitudinal oncologist ; patient neuroendocrine tumor still exclude moderate severe cohort Note : romidepsin approve patient relapsed refractory peripheral Tcell lymphoma ( PTCL ) cutaneous T cell lymphoma ( CTCL ) , patient would eligible WITHOUT requirement 'relapsed within 6 month last treatment ' Life expectancy &gt; 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Hemoglobin &gt; = 9 g/dL ( transfusion and/or erythropoietin permit ) Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L Platelets &gt; = 100 x 10^9/L ( platelet count &gt; = 30 Ã— 10^9 cells/L patient lymphoma CLL bone marrow disease involvement document ) Creatinine = &lt; twice upper limit institutional normal Patients abnormal liver function eligible group accord criterion Group A ( normal hepatic function ) Bilirubin = &lt; upper limit normal ( ULN ) aspartate aminotransferase ( AST ) = &lt; ULN Group B ( mild hepatic dysfunction ) B1 : bilirubin = &lt; ULN AST &gt; ULN B2 : bilirubin &gt; ULN = &lt; 1.5 x ULN AST Group C ( moderate hepatic dysfunction ) Bilirubin &gt; 1.5 x ULN = &lt; 3 x ULN AST Group D ( severe hepatic dysfunction ) Bilirubin &gt; 3 x ULN investigator discretion AST Patients active hemolysis exclude ; distinction make liver dysfunction due metastasis liver dysfunction due cause ; registration laboratory investigation use assign patient hepatic function group ; liver function test repeat within 24 hour prior start initial therapy may result patient ' group assignment alter different registration test result Patients brain metastasis require corticosteroid nonenzyme induce anticonvulsant must stable dose corticosteroid seizure free 1 month prior enrollment ; patient know brain metastasis complete brain irradiation ( whole brain gamma knife ) 4 week start protocol ; patient enzyme induce anticonvulsant eligible ; note patient steroid taper low dose ( i.e . &lt; 1.5 mg dexamethasone/day ) due potential high dexamethasone dose induce cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) Patients biliary obstruction stent place eligible , provide shunt place least 10 day prior first dose romidepsin liver function stabilize ; two measurement least 2 day apart put patient hepatic dysfunction stratum accept evidence stable hepatic function ; evidence biliary sepsis Eligibility patient receive medication substance know affect potential affect activity PK romidepsin determine follow review case site principal investigator Patients treat medication prohibit must discontinue use least 7 day prior first dose romidepsin ; certain agent interact CYP3A4 system may use caution Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately ; note : since romidepsin bind estrogen receptor , effectiveness estrogen contain contraceptive may reduce Human immunodeficiency virus ( HIV ) positive patient receive : agent potential PK interaction romidepsin hepatotoxic antiretrovirals ( nucleoside reversetranscriptase inhibitor [ NRTIs ] : abacavir , didanosine , emtricitabine , lamivudine , stavudine , zidovudine ) , dual protease inhibitor ( PI ) base regimen except lowdose boost ritonavir , atazanavir , indinavir , maraviroc , nevirapine may eligible ; additionally , HIVpositive patient cluster differentiation ( CD ) 4 count &gt; 250/mm^3 ; specific cause hepatic dysfunction unknown , patient work viral cause hepatitis eligibility determine consultation principal investigator Patients receive prior romidepsin use eligible Ability understand willingness sign write informed consent document Patients ( prior enter study ) : major surgery permit within 4 week romidepsin administration ; anticancer therapy include chemotherapy , radiotherapy , hormonal ( exception hormone thyroid condition ) , investigational agent allow within 14 day five ( 5 ) halflives ( whichever longer ) prior first dose romidepsin ( 6 week nitrosoureas mitomycin C ) ; additionally , participant must recover less grade 2 clinically significant adverse effect ( ) /toxicity ( y ) previous therapy , exception alopecia , unless approve principal investigator ; biologics immunotherapy allow within 28 day prior , , romidepsin administration Patients prostate cancer , renal cell cancer , neuroendocrine tumor , lung cancer , colorectal cancer , soft tissue sarcoma , glioma , thyroid cancer exclude normal mild cohort due lack efficacy tumor type phase 2 study ; patient prostate cancer , renal cell cancer , lung cancer , colorectal cancer , soft tissue sarcoma , glioma thyroid cancer allow enroll moderate severe cohort ; patient neuroendocrine tumor still exclude moderate severe cohort Patients may receive investigational agent History allergic reaction attribute compound similar chemical biologic composition romidepsin , include cyclic tetrapeptide compound Concurrent medication associate know risk correct QT interval ( QTc ) prolongation and/or Torsades de Pointes allow within 2 week initiation study treatment ; medication list possible risk cause QTc prolongation Torsades de Pointes allow , although alternative medication substitute , would preferable ; granisetron acceptable antiemetic study , patient must take ondansetron , may NOT take concomitant agent might impact QTc Thiazolidinedione agents rosiglitazone pioglitazone permit Uncontrolled intercurrent illness include , limited ongoing active infection , psychiatric illness/social situation would limit compliance study requirement Patients current evidence significant cardiovascular disease ( New York Heart Association class III IV cardiac disease ) , symptomatic congestive heart failure , dilated/hypertrophic restrictive cardiomyopathy , myocardial infarction ( within past 6 month ) , unstable angina , unstable arrhythmia need antiarrhythmic therapy ( use medication rate control atrial fibrillation allow calcium channel blocker betablockers , stable medication least last month prior initiation romidepsin treatment medication list cause Torsades de Pointes ) , evidence acute ischemia electrocardiogram ( ECG ) ; mark baseline prolongation QT/QTc interval , e.g. , repeat demonstration QTc interval &gt; 450 msec* ; long QT syndrome ; require use concomitant medication may cause Torsades de Pointes may cause significant prolongation QTc Note : due difficulty assess QTc patient heart block , may eligible deemed safe cardiologist ; patient must take ondansetron antiemetic , QTc may NOT 450 ( exception patient heart block ) Pregnant woman exclude study ; breastfeed discontinue mother treated drug Warfarin permit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>